Federal contract award
75A50124C00039
EMORY UNIVERSITY- FLUVID, A DRY POWDER, INHALED, MRNA-BASED TREATMENT FOR INFLUENZA AND COVID
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $490.4K |
| Current contract value | $490.4K |
| Potential contract value / ceiling | $490.4K |
| Start date | Aug 22, 2024 |
| Current end date | Aug 5, 2025 |
| Potential end date | Aug 5, 2025 |
| Latest award activity | Oct 31, 2025 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Oct 31, 2025 | P00002 | $-259.6K | EMORY UNIVERSITY- FLUVID, A DRY POWDER, INHALED, MRNA-BASED TREATMENT FOR INFLUENZA AND COVID |
| Feb 12, 2025 | P00001 | $0 | EMORY UNIVERSITY- FLUVID, A DRY POWDER, INHALED, MRNA-BASED TREATMENT FOR INFLUENZA AND COVID |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.